1,695 results match your criteria Tumor Lysis Syndrome


A case of pure erythroid leukemia with MYB-GATA1 fusion that developed tumor lysis syndrome with dexamethasone.

Pediatr Blood Cancer 2020 Jul 7:e28285. Epub 2020 Jul 7.

Department of Hematology/Oncology, Nagano Children's Hospital, Azumino, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.28285DOI Listing

Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.

Ann Hematol 2020 Jul 3. Epub 2020 Jul 3.

Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, 2 Yude Rd, North District, Taichung, 404, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04168-2DOI Listing

Leukostasis in Chronic Lymphocytic Leukemia.

Am J Case Rep 2020 Jul 3;21:e924798. Epub 2020 Jul 3.

Department of Medicine, Division of Hematology and Oncology, State University New York (SUNY) Downstate Medical Center, Brooklyn, NY, USA.

BACKGROUND Chronic lymphocytic leukemia (CLL) is a mature B cell lymphocytic neoplasm that has an indolent clinical course. Therefore, not all patients with CLL require treatment at the time of diagnosis. Hyperleukocytosis (white blood cell count, >100×10⁹/L) is present in a large proportion of patients with CLL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/AJCR.924798DOI Listing

Acute kidney injury with extreme hyperuricemia after antithymocyte globulin treatment in a kidney transplant recipient with underlying aplastic anemia: a case report.

BMC Nephrol 2020 Jul 2;21(1):251. Epub 2020 Jul 2.

Division of Nephrology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, South Korea.

Background: The occurrences of hyperuricemia and acute kidney injury after antithymocyte globulin treatment are unusual in kidney transplant recipients. Here, we report a unique case of acute kidney injury with extreme hyperuricemia after antithymocyte globulin treatment in a kidney transplant recipient with underlying aplastic anemia.

Case Presentation: A 40-year-old woman with aplastic anemia who received a kidney transplant 5 years 6 months before presented to our emergency department with complaints of oliguria, generalized edema, and general weakness 6 days after receiving antithymocyte globulin treatment for acute T-cell-mediated rejection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12882-020-01903-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330935PMC

Treatment-Emergent Tumor Lysis Syndrome With PI3Kδ-γ Inhibition After CAR T-Cell Therapy for Chronic Lymphocytic Leukemia.

JCO Oncol Pract 2020 Jun 30:OP2000022. Epub 2020 Jun 30.

Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/OP.20.00022DOI Listing

A Retrospective Review of Tumor Lysis Syndrome Associated With Colorectal Cancer.

Cureus 2020 May 24;12(5):e8257. Epub 2020 May 24.

Genitourinary Oncology, Creighton University School of Medicine/University of Arizona Cancer Center at Dignity Health, Phoenix, USA.

Tumor lysis syndrome (TLS) is a life-threatening oncologic condition that is most commonly linked with hematologic malignancies and uncommonly seen in solid tumors, including colorectal cancer (CRC). Therefore, a lack of awareness regarding TLS in CRC could lead to significant morbidity and mortality. This study aims to explore the clinical characteristics and outcomes of TLS in patients with CRC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.8257DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313428PMC

Tumor lysis syndrome in a patient with metastatic melanoma treated with nivolumab.

Clin J Gastroenterol 2020 Jun 27. Epub 2020 Jun 27.

Department of Gastroenterology, Kanazawa University Hospital, 13-1 Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan.

A 79-year-old man with metastatic melanoma of the right maxillary sinus and multiple liver metastases received a single dose of nivolumab. Eight days later, he experienced impaired consciousness, accompanied by abnormal laboratory and electrocardiographic findings. He was therefore diagnosed with tumor lysis syndrome (TLS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12328-020-01164-xDOI Listing

A Rare Case of T-Cell Lymphoma Presenting with Bilateral Nephrolithiasis and Acute Renal Failure.

Urology 2020 Jun 24. Epub 2020 Jun 24.

Department of Urology, University of Oklahoma HSC, Children's Hospital at OU Medical Center, Oklahoma City, OK. Electronic address:

We present the rare case of a young boy who was found to have T-cell lymphoma after presenting with flank pain and bilateral nephrolithiasis. He initially underwent bilateral ureteral stent placement but returned with oliguria and acute renal failure. His subsequent workup revealed lymphoma involving both kidneys. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2020.06.013DOI Listing

Tumor Lysis Syndrome Caused by Unrecognized Richter's Transformation of Chronic Lymphocytic Leukemia: Treatment With Venetoclax for Suspected Disease Progression.

Cureus 2020 May 15;12(5):e8145. Epub 2020 May 15.

Internal Medicine, University of Connecticut Health Center, Farmington, USA.

Richter's transformation (RT) is defined as the transition of chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) into an aggressive lymphoma. The conversion generally leads to diffuse large B-cell lymphoma (DLBCL), but more aggressive forms such as Hodgkin lymphoma (HL) can also occur. RT is a rare complication of CLL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.8145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294869PMC

A rare cause of tumour lysis syndrome and acute kidney injury.

J R Coll Physicians Edinb 2020 Mar;50(1):35-38

Baghdad Teaching Hospital, The Medical City, Baghdad, Iraq.

Tumour lysis syndrome is rare in solid malignancies. Here, we report a case of tumour lysis syndrome and acute kidney injury in a 23-year-old female with gestational trophoblastic neoplasia. Hydration and early dialysis therapy were started with good recovery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4997/JRCPE.2020.109DOI Listing

Tumor Lysis Syndrome in a Patient With Gastric Adenocarcinoma.

J Investig Med High Impact Case Rep 2020 Jan-Dec;8:2324709620933427

John H Stroger Hospital of Cook County, Chicago, IL, USA.

Tumor lysis syndrome (TLS) is a severe metabolic complication that usually occurs in patients with aggressive tumors who undergo treatment with chemotherapy. Traditionally, it was mainly associated with hematologic malignancies. However, over the past 4 decades, there have been increasing reports of TLS in solid tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2324709620933427DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294369PMC

Electrolyte Disorders Induced by Antineoplastic Drugs.

Front Oncol 2020 19;10:779. Epub 2020 May 19.

Unità di Ricerca Cardiorenale, Clinica e Terapia Medica, Dipartimento di Medicina e Chirurgia (DIMEC), University of Parma, Parma, Italy.

The use of antineoplastic drugs has a central role in treatment of patients affected by cancer but is often associated with numerous electrolyte derangements which, in many cases, could represent life-threatening conditions. In fact, while several anti-cancer agents can interfere with kidney function leading to acute kidney injury, proteinuria, and hypertension, in many cases alterations of electrolyte tubular handling and water balance occur. This review summarizes the mechanisms underlying the disturbances of sodium, potassium, magnesium, calcium, and phosphate metabolism during anti-cancer treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00779DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248368PMC

Fatal Spontaneous Tumor Lysis Syndrome in a Patient with Metastatic Colon Cancer: A Clinical Case of Rare Oncological Emergency.

Case Rep Gastroenterol 2020 May-Aug;14(2):255-260. Epub 2020 May 7.

Department of Internal Medicine, Hospital Harzklinikum Dorothea Christiane Erxleben GmbH, Wernigerode, Germany.

Tumor lysis syndrome (TLS) is a potentially life-threatening complication of chemotherapy. It usually occurs in rapidly proliferating hematological malignancies. TLS is deemed spontaneous (STLS) when it occurs prior to any cytotoxic or definite treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507648DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250380PMC

Tumor Lysis Syndrome in Solid Tumors: A Comprehensive Literature Review, New Insights, and Novel Strategies to Improve Outcomes.

Cureus 2020 May 29;12(5):e8355. Epub 2020 May 29.

Genitourinary Oncology, Creighton University School of Medicine/University of Arizona Cancer Center at Dignity Health, Phoenix, USA.

Tumor lysis syndrome (TLS) is a life-threatening oncological condition that is typically characterized by metabolic derangements that are often labeled as an acute kidney injury. The recent advancement in cancer treatment has led to the mounting rate of TLS in solid tumors that were previously rarely linked to this complication. Given that its prognosis is dismal, it is essential to increase recognition of this condition by describing more sensitive markers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.8355DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263728PMC

Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies.

J Immunother Cancer 2020 May;8(1)

Department of Immunology, University of Tübingen Interfaculty Institute of Cell Biology, Tubingen, Germany

Bispecific antibodies (bsAb) and chimeric antigen receptor (CAR) T cells allow for antibody guided recruitment of T cells against tumors. Both are successfully used for treatment of CD19 expressing leukemias, but may cause cytokine release syndrome (CRS) as a major dose-limiting side effect. For CRS prevention, steroids are recommended prior to bsAb treatment, despite their well-known lymphotoxic activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jitc-2020-000621DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264835PMC

Pediatric Case of Successful Point-of-Care Ultrasound-Guided Nasogastric Tube Placement.

J Emerg Med 2020 May 23. Epub 2020 May 23.

Division of Pediatric Emergency Medicine, Department of Pediatric Emergency and Critical Care Medicine, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.

Background: Nasogastric tube (NGT) placement is commonly performed in pediatric emergency care and is classically confirmed by any one of several methods, among which auscultation or aspiration and radiography comprise the currently recognized as the reference standard. Point-of-care ultrasound (POCUS) is used to confirm NGT insertion, especially in adults or prehospital patients, but reports of its use in the pediatric emergency department (ED) are still scarce. We report a case of successful POCUS-guided NGT placement in a pediatric ED. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jemermed.2020.04.029DOI Listing

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.

J Clin Oncol 2020 May 26:JCO2000303. Epub 2020 May 26.

Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD.

Purpose: Burkitt lymphoma is an aggressive B-cell lymphoma curable with dose-intensive chemotherapy derived from pediatric leukemia regimens. Treatment is acutely toxic with late sequelae. We hypothesized that dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R) may obviate the need for highly dose-intensive chemotherapy in adults with Burkitt lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.20.00303DOI Listing
May 2020
18.428 Impact Factor

Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice.

Leuk Lymphoma 2020 May 25:1-6. Epub 2020 May 25.

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

The risk of TLS in patients with relapsed CLL treated outside of clinical trials is not well described. Using the Mayo Clinic CLL Database, 48 patients treated with venetoclax for relapsed CLL in routine practice were identified; chart review determined baseline risk for TLS and laboratory abnormalities during venetoclax ramp-up. Overall, 6 (13%) patients developed laboratory TLS, 3 of whom demonstrated clinical TLS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1768384DOI Listing

[Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia].

Rinsho Ketsueki 2020 ;61(4):322-326

Department of Hematology/Oncology, Saitama Children's Medical Center.

Gilteritinib is an FMS-like tyrosine kinase 3 (FLT3) inhibitor that has shown efficacy in patients with refractory or recurrent adult acute myeloid leukemia (AML) with FLT3 mutations. However, there are limited data for pediatric patients treated with this drug. Herein, we report the clinical courses of two children with FLT3-mutated recurrent AML who received gilteritinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.61.322DOI Listing
January 2020

Steroid-induced Lactic Acidosis in Diffuse Large B-cell Lymphoma.

Cureus 2020 Mar 28;12(3):e7446. Epub 2020 Mar 28.

Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, USA.

A previously healthy 53-year-old male with primary membranous nephropathy (positive anti phospholipase A2 antibody) presented to our hospital with worsening cough, shortness of breath, hypotension, and malaise. During his hospital stay, he quickly progressed to overt respiratory failure requiring mechanical ventilation. Upon further workup, he met clinical criteria for tumor lysis syndrome due to an unknown diffuse large B-cell lymphoma, who underwent rapid cytolysis after starting stress dose steroids. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7446DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186090PMC

Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma.

Case Rep Oncol 2020 Jan-Apr;13(1):249-254. Epub 2020 Mar 24.

Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Nivolumab, a programmed death-1 checkpoint inhibitor, is worldwide available for metastatic renal cell carcinoma (mRCC). Limited data exist on the response to vascular endothelial growth factor receptor-tyrosine kinase inhibitor (TKI) therapy after administration of nivolu-mab. In this case study, we report on a patient with tumor lysis syndrome (TLS), which was induced by pazopanib after the administration of nivolumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506196DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154254PMC

The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat.

Cancers (Basel) 2020 Apr 9;12(4). Epub 2020 Apr 9.

Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University, 770-8503 Tokushima, Japan.

Receptor activator of NF-κB ligand (RANKL), a critical mediator of osteoclastogenesis, is upregulated in multiple myeloma (MM). The xanthine oxidase inhibitor febuxostat, clinically used for prevention of tumor lysis syndrome, has been demonstrated to effectively inhibit not only the generation of uric acid but also the formation of reactive oxygen species (ROS). ROS has been demonstrated to mediate RANKL-mediated osteoclastogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12040929DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226249PMC

Spontaneous Tumor Lysis Syndrome Due to Endometrial Carcinoma.

Cureus 2020 Mar 9;12(3):e7220. Epub 2020 Mar 9.

Internal Medicine, University of Connecticut, Farmington, USA.

Spontaneous tumor lysis syndrome (TLS) is a rare condition in solid tumors, particularly in endometrial carcinoma. Spontaneous TLS occurs without the use of cytotoxic therapy but is observed particularly in hematologic malignancies. Given the high morbidity and mortality associated with spontaneous TLS, it is crucial to identify and treat it promptly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7220DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141803PMC

Pembrolizumab-axitinib-induced tumor lysis syndrome in a patient with metastatic renal cancer.

Clin Case Rep 2020 Apr 15;8(4):704-708. Epub 2020 Feb 15.

Internal Medicine Morehouse School of Medicine Grady Memorial Hospital Atlanta Georgia.

Tumor lysis syndrome is uncommon in solid tumors but with the use of immunotherapy (checkpoint inhibitors) their incidence is increasing. Physicians need to take adequate precautions while treating patients with immunotherapy. The findings of our case report will help improve our current understanding of tumor lysis syndrome specially in solid tumors and will help in developing multidisciplinary treatment and prophylaxis strategies for this uncommon, but potentially fatal complication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.2737DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141709PMC

Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?

Int J Hematol 2020 May 6;111(5):642-656. Epub 2020 Apr 6.

Department of Hematology, Endocrinology and Metabolism, Niigata University, Faculty of Medicine, Niigata, Japan.

Advances in the molecular biology of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and development of molecularly targeted therapies have resulted in treatment innovations. Therapeutic approaches for previously untreated CLL/SLL patients are changing from chemoimmunotherapy (CIT) to molecularly targeted drugs. The aim of therapy for CLL patients has been to control the disease; however, FCR (fludarabine, cyclophosphamide, rituximab) has improved outcomes and reduced the high incidence of undetectable minimum/measurable residual disease (MRD) in previously untreated CLL patients with no 17p deletion/TP53 disruption and mutated immunoglobulin heavy chain gene (IGHV). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-020-02867-0DOI Listing

Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits.

Expert Rev Hematol 2020 May 17;13(5):489-499. Epub 2020 Apr 17.

Division of Hematology, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA.

: Hyperleukocytosis, defined as a total white blood cell count (WBC) >50 or more commonly >100 × 10 cells/L, is a presenting feature of acute myeloid leukemia (AML) in about 6-20% of cases and is associated with a higher risk of tumor lysis syndrome (TLS), disseminated intravascular coagulation (DIC), clinical leukostasis with end organ damage, and mortality.: In this review, authors discuss the implications of hyperleukocytosis in AML and the current understanding of cytoreductive strategies with a focus on the use of leukocytapheresis.: Efforts to rapidly reduce peripheral myeloblasts have included the use of leukocytapheresis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2020.1751609DOI Listing

Intricate Interplay of Entwined Metabolic and Inflammatory Life-threatening Processes in Tumor Lysis Syndrome Complicating Prostate Cancer: A Systematic Review with a Single Institution Experience.

Cureus 2020 Mar 24;12(3):e7395. Epub 2020 Mar 24.

Genitourinary Oncology, Creighton University School of Medicine / University of Arizona Cancer Center at Dignity Health St. Joseph's, Phoenix, USA.

Tumor lysis syndrome (TLS) occurs in rapidly proliferating tumor cells, either spontaneously or after cytotoxic therapy. It has been well-documented in hematological diseases but is extremely rare in solid neoplasms, particularly in prostate cancer (PRCA). In the presence of risk factors, it can cause metabolic disturbances and be potentially fatal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7395DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096067PMC

Tuberculosis and Tumor Lysis Syndrome-Coincidence or Coexistent: A Case Report.

Indian J Crit Care Med 2020 Feb;24(2):145-147

Department of Pediatric Critical Care, St. John's Medical College, Bengaluru, Karnataka, India.

Extrapulmonary tuberculosis (TB) involving bone marrow can present with various manifestations, including pancytopenia, maturation arrest, hemophagocytic lymphohistiocytosis (HLH), or infiltration of the bone marrow by caseating or noncaseating granulomas causing reversible or irreversible fibrosis. Tumor lysis syndrome (TLS) is an oncologic emergency resulting from massive tumor cell lysis. Children with TB with bone marrow involvement may also present with laboratory features of TLS resulting from high catabolism and concomitant acute kidney injury (AKI), making the diagnosis difficult at times. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5005/jp-journals-10071-23359DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075064PMC
February 2020

[Recommendations for tumor lysis syndrome management].

Authors:

Arch Argent Pediatr 2020 04;118(2):S59-S63

The tumor lysis syndrome represents a potentially lethal complication caused by the massive release of nucleic acids, potassium and phosphate into the circulation as a result of the lysis of neoplastic cells, which are characterized by a rapid proliferation capacity and high sensitivity to drugs. This may occur spontaneously prior to the start of treatment, becoming worse after the initiation of chemotherapy. It presents a high mortality; its prevention continues being the most important therapeutic measure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5546/aap.2020.S59DOI Listing

STAT: Tumor Lysis Syndrome.

Authors:

Clin J Oncol Nurs 2020 Apr;24(2):216

Tumor lysis syndrome is when large numbers of rapidly dividing cells are killed and release their contents into the bloodstream. . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1188/20.CJON.216DOI Listing

Synchronous Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Metastatic Squamous Cell Carcinoma of the Cervix Involving the Coronary Arteries Leading to Acute Myocardial Infarction.

Case Rep Oncol Med 2020 21;2020:6192754. Epub 2020 Feb 21.

SUNY Upstate Medical University Hospital, 750 E Adams St., Syracuse, NY 13210, USA.

A 66-year-old woman presented to the hospital with a one-month history of shortness of breath, fatigue, and postmenopausal vaginal bleeding and a one-week history of chest pain. This case report discusses the rare synchronous occurrence of two different malignancies in the setting of non-ST segment elevation myocardial infarction and the relation between these unfortunate events. Besides the case presented in this report, there have been only 13 reported cases of synchronous chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) associated with metastatic squamous cell carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/6192754DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060405PMC
February 2020

Tumor lysis syndrome in childhood malignancies.

Drugs Context 2020 25;9. Epub 2020 Feb 25.

Department of Pediatrics, The University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada.

Background: Tumor lysis syndrome (TLS) is the most common life-threatening oncological emergency encountered by physicians treating children with lymphoproliferative malignancies. Healthcare providers should be aware of the condition in order to prevent occurrence and prompt timely management to avoid severe consequences.

Objective: To provide an update on the current understanding, evaluation, and management of tumor lysis syndrome in childhood malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7573/dic.2019-8-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048108PMC
February 2020

Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.

Lancet Haematol 2020 Apr 5;7(4):e309-e319. Epub 2020 Mar 5.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Mutations in isocitrate dehydrogenase-2 (IDH2) occur in around 5% of patients with myelodysplastic syndromes. Neomorphic activity of mutant IDH2 proteins results in hypermethylation of DNA and histones, leading to blocked haemopoietic differentiation. Enasidenib, an inhibitor of mutated IDH2 proteins, induces responses in patients with IDH2-mutated, relapsed or refractory acute myeloid leukaemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(19)30284-4DOI Listing

Burkitt and Burkitt-Like Lymphomas: a Systematic Review.

Curr Oncol Rep 2020 Mar 6;22(4):33. Epub 2020 Mar 6.

Département d'Hématologie, Institut de Cancérologie Gustave Roussy, 114 Rue Edouard Vaillant, 94810, Villejuif, France.

Purpose Of Review: Burkitt's lymphoma and its leukemic form (Burkitt cell acute lymphoblastic leukemia) are a highly aggressive disease. We review the classification, clinical presentation, histology, cytogenetics, and the treatment of the disease.

Recent Findings: Burkitt's lymphoma might be associated with tumor lysis syndrome which is a potentially fatal complication that occurs spontaneously or upon initiation of chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-020-0898-8DOI Listing

Hepatic Portal Venous Gas: An Ill Omen or a Misleading Sign.

Surg J (N Y) 2020 Jan 3;6(1):e37-e41. Epub 2020 Mar 3.

Department of Internal Medicine and Medical Gastroenterology, Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India.

Hepatic portal venous gas (HPVG), a rare radiological finding, is historically considered an ominous sign with 100% mortality rates. The dictum that HPVG warrants surgical intervention is challenged in the recent literature. This is because of the identification of various causes of HVPG other than bowel gangrene. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0040-1702919DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054055PMC
January 2020

Tumor lysis syndrome as a risk factor for very early mortality in HIV-associated non-Hodgkin's lymphoma: A 10-year single-center experience.

J Chin Med Assoc 2020 Apr;83(4):371-376

Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.

Background: Despite the effectiveness of combination antiretroviral therapy, persons living with human immunodeficiency virus (PLWHIV) remain at a high risk of developing non-Hodgkin lymphoma (NHL). We aimed to analyze the demographics and outcomes of the HIV-associated NHLs.

Methods: Between 2005 and 2014, PLWHIV with NHLs were retrospectively enrolled at a tertiary referral center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JCMA.0000000000000279DOI Listing

Bruton's tyrosine kinase inhibitors and the kidney: Focus on ibrutinib.

J Oncol Pharm Pract 2020 Feb 13:1078155220904406. Epub 2020 Feb 13.

Department of Medicine, Mount Sinai Beth Israel Medical Center, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155220904406DOI Listing
February 2020

Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.

Clin Lymphoma Myeloma Leuk 2020 Apr 30;20(4):212-218. Epub 2019 Sep 30.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

Background: Patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) have dismal outcomes. Preclinical studies have suggested that T-ALL cells are sensitive to BCL2 inhibition. The clinical activity of venetoclax, a selective BCL2 inhibitor, in T-ALL is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.09.608DOI Listing

Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations.

Lancet Haematol 2020 Feb;7(2):e168-e176

Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

Tumour lysis syndrome is a complication of chemotherapy for haematological malignancies; in particular, aggressive leukaemias and lymphomas. For haematological malignancies, targeted therapies, such as small molecule inhibitors and monoclonal antibodies, have a high anti-tumour activity, are well tolerated, and have a low incidence of associated tumour lysis syndrome. The BCL-2 inhibitor venetoclax has a high anti-tumour activity in chronic lymphocytic leukaemia, achieving deep remissions by potently inducing apoptosis and increasing the risk for tumour lysis syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(19)30253-4DOI Listing
February 2020

Co-existence of follicular lymphoma in the lymph node with High-grade B cell lymphoma in the bone marrow of a patient presenting with spontaneous tumor lysis syndrome.

Cardiovasc Hematol Disord Drug Targets 2020 Jan 29. Epub 2020 Jan 29.

Department of Internal Medicine, Evangelismos General Hospital, Athens, Greece.

A significant percentage of B-cell lymphomas are characterized by bone marrow involvement (BMI) at diagnosis. In most cases, there is concordance between the type of lymphoma present in the lymph node and the lymphoma present in the bone marrow. Herein, we present a sixty-seven years old female patient, who was diagnosed with High-Grade B-cell Lymphoma (HGBL) in the bone marrow, while simultaneously, in the peripheral lymph node, the presence of Follicular Lymphoma (FL) was noted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871529X20666200130095417DOI Listing
January 2020

Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity.

Hematol Oncol 2020 Apr 27;38(2):204-206. Epub 2020 Jan 27.

Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and Ospedale Maggiore della Carità, Novara, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2700DOI Listing

Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax.

Ann Hematol 2020 Mar 21;99(3):501-511. Epub 2020 Jan 21.

Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Venetoclax, a selective B cell leukemia/lymphoma-2 (BCL2) inhibitor, has recently shown activity in relapsed or refractory (R/R) acute myeloid leukemia (AML). Effective biomarkers for identifying patients most likely to respond to venetoclax-based treatment are of clinical utility. In this study, we aimed to evaluate the efficacy and safety profiles of venetoclax-based therapy in a total 40 R/R AML patients and identify the potentially predictive factors for response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-03911-zDOI Listing

Acute Liver Failure as the Leading Manifestation of Spontaneous Tumour Lysis Syndrome in a Patient with NonHodgkin Lymphoma: Do Current Diagnostic Criteria of Tumour Lysis Syndrome Need Re-Evaluation?

Case Rep Crit Care 2019 26;2019:2358562. Epub 2019 Dec 26.

Department of Anaesthesiology and Intensive Care Medicine, Clinical Hospital Centre Rijeka, Krešimirova 42, 51000 Rijeka, Croatia.

Tumour lysis syndrome (TLS) is a group of pathophysiological processes caused by rapid degradation of tumour cells with subsequent release of intracellular contents into the extracellular space. It is characterized by the development of systemic metabolic disturbances with or without clinical manifestations. The process usually occurs in highly proliferative, large tumours after induction of cytotoxic therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/2358562DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948293PMC
December 2019

Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.

Leuk Res 2020 Feb 7;89:106298. Epub 2020 Jan 7.

Division of Hematology, University of Washington School of Medicine, Seattle, WA, USA. Electronic address:

While rasburicase has shown efficacy to rapidly correct hyperuricemia compared with allopurinol, its overall impact in improving clinically significant outcomes, such as acute kidney injury (AKI), in tumor lysis syndrome (TLS) is unknown. In this retrospective cohort study, we included all hospitalized cancer patients with hyperuricemia and AKI who received rasburicase +/- allopurinol or allopurinol alone from 2009 to 2015. Inverse probability of treatment weighting using propensity score was used to account for potential confounders and to estimate the causal effect associated with differential drug treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2020.106298DOI Listing
February 2020

A rare cause of vomiting in an adolescent: gastric Burkitt`s lymphoma.

Turk J Pediatr 2019 ;61(3):431-435

Departments of Pediatric Gastroenterology, Hepatology and Nutrition, Erciyes University Faculty of Medicine, Kayseri, Turkey.

Altay D, Özcan A, Ünal E, Deniz K, Özkan KU, Patıroğlu T, Arslan D. A rare cause of vomiting in an adolescent: gastric Burkitt`s lymphoma. Turk J Pediatr 2019; 61: 431-435. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24953/turkjped.2019.03.018DOI Listing
January 2019

Tumor Lysis Syndrome.

Pediatr Rev 2020 Jan;41(1):20-26

Section of Pediatric Hematology/Oncology, Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1542/pir.2018-0243DOI Listing
January 2020

You Can't Always Blame the Chemo: A Rare Case of Spontaneous Tumor Lysis Syndrome in a Patient with Invasive Ductal Cell Carcinoma of the Breast.

Cureus 2019 Nov 18;11(11):e6186. Epub 2019 Nov 18.

Hematology Oncology, Crozer Chester Medical Center, Upland, USA.

Tumor lysis syndrome (TLS) is an oncologic emergency characterized by metabolic and electrolyte abnormalities, observed during the destruction of tumor cells. While it is commonly seen during cytotoxic treatment of hematologic malignancies, it is rarely seen or suspected in solid tumors. The incidence of spontaneous tumor lysis (before cancer treatment) in solid malignancies is even rarer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.6186DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6919952PMC
November 2019

Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia.

Authors:
John G Gribben

Br J Haematol 2020 Mar 19;188(6):844-851. Epub 2019 Dec 19.

Barts Cancer Institute, St. Bartholomew's Hospital, Queen Mary University of London, London, UK.

The treatment landscape in relapsed/refractory chronic lymphocytic leukaemia (CLL) has rapidly evolved over the past five years, with one such emergent treatment being the BCL2 inhibitor, venetoclax. This oral treatment has demonstrated significant clinical advantages in indicated patients, but rapid tumour debulking can lead to a treatment-related risk of the acute condition known as tumour lysis syndrome (TLS). Here, I present real patient cases to show how I have used the recommended predose monitoring and prophylactic procedures to mitigate the risk of TLS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16345DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154710PMC

Clinical Interventions to Prevent Tumour Lysis Syndrome in Hematologic Malignancy: A Multisite Retrospective Chart Review.

Can J Hosp Pharm 2019 Nov-Dec;72(6):435-445. Epub 2019 Dec 1.

PharmD, is with the Department of Pharmacy, Mount Sinai Hospital, Sinai Health System, and the Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario.

Background: Tumour lysis syndrome (TLS) occurs when lysis of malignant cells causes electrolyte disturbances and potentially organ dysfunction. Guidelines recommending preventive therapy according to TLS risk are based on low-quality evidence.

Objectives: The primary objective was to characterize utilization of TLS preventive strategies through comprehensive description of current practice. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6910844PMC
December 2019

Clinical characterization and prognosis of T cell acute lymphoblastic leukemia with high CRLF2 gene expression in children.

PLoS One 2019 12;14(12):e0224652. Epub 2019 Dec 12.

Department of Hematology, Children's Hospital of Chongqing Medical University, Chongqing, P.R. China.

It has been reported that overexpression of the CRLF2 gene is associated with poor outcomes in pediatric B cell acute lymphoblastic leukemia (B-ALL), but the incidence rates, clinical characteristics and outcomes of CRLF2 gene overexpression in pediatric T cell ALL (T-ALL) have not been systematically analyzed. In this study, CRLF2 mRNA expression levels and clinical and laboratory parameters in 63 pediatric T-ALL patients were detected at the Children's Hospital of Chongqing Medical University and Children's Hospital of Xianyang between February 2015 and June 2018. The patients were treated according to the modified St. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0224652PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907766PMC